Emerging Cellular Therapies: Cancer and Beyond
joint with Engineering the Genome
Organizer(s): Crystal L. Mackall, Marina Cavazzana and Stanley R. RiddellDate: February 08 - 12, 2020
Location: Fairmont Banff Springs, Banff, AB, Canada
After many years of fundamental research, cell-based therapies are now recognized as effective medicines for treatment of a specific subset of cancers as well as a growing list of autoimmune, degenerative and infectious diseases. This clinical progress has been propelled by exponential growth in understanding of the underlying cell biology, and increasingly sophisticated techniques for genetic engineering and for using synthetic biology to control cellular therapeutics. Cellular therapeutics are now poised for increasing impact both in cancer medicine and in the treatment of genetic, autoimmune and degenerative diseases. This conference will bring together fundamental researchers and translational scientists to discuss recent successes and highlight challenges across the spectrum of emerging cellular therapeutics. Another innovative aspect of this conference is the joint pairing with the Keystone Symposia conference on “Engineering the Genome” organized by Drs. Vic Myer and Erik Sontheimer. This unique pairing will provide an outstanding opportunity to cross-fertilize ideas and to facilitate formation of new collaborations between experts in genome engineering and experts in cell biology, cell-based therapies and synthetic biology. The conference will provide an opportunity to report emerging preclinical and clinical insights, present novel platforms, and highlight challenges related to both safety and efficacy of cell therapies. The broad disease focus will enhance collaborations between the cancer immunotherapy communities and those focused on developing cell therapies for non-malignant disease.
Scholarship Deadline: October 29 2019
Discounted Abstract Deadline: October 29 2019
Abstract Deadline: November 6 2019
Discounted Registration Deadline: December 10 2019
We gratefully acknowledge additional support from these exhibitors at this conference:
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
Fate Therapeutics, Inc.
We gratefully acknowledge the generous grant for this conference provided by:National Cancer Institute (NCI)
Grant No. 1R13CA243398-01
Funding for this conference was made possible (in part) by 1R13CA243398-01 from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.